Atlanta, GANCT07252050Now EnrollingIRB Ready

Sickle Cell Disease Clinical Trial in Atlanta, GA

Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Arkansas Children's Hospital Research Institute

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access sickle cell disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sickle cell disease treatment provided free

Apply for This Atlanta Location

Check if you qualify for this sickle cell disease clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Sickle Cell Disease Study in Atlanta

This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.

Sponsor: Arkansas Children's Hospital Research Institute

Who Can Participate

Inclusion Criteria

Participants with any genotypic form of SCD aged 12 - 45 years at enrollment with ≥1 of the following:
History of stroke and/or vasculopathy, including evidence of asymptomatic cerebrovascular disease for pediatric patients.
Recurrent moderate-severe acute chest syndrome (ACS)
Recurrent vaso-occlusive pain episodes requiring parenteral analgesia despite the institution of supportive care.
Need for chronic transfusion therapy to prevent vaso-occlusive complications (i.e. pain, stroke, and ACS).
For adult patients, an echocardiographic finding of tricuspid valve regurgitant jet velocity (TRJV) ≥ 2.7 m/sec.
Participants must have an HLA haploidentical first degree relative (parent, sibling, or half sibling) who is willing and able to donate bone marrow.
Participants must meet institutional eligibility criteria for HCT.

Exclusion Criteria

Presence of an HLA-matched sibling who is willing and able to donate bone marrow.
Uncontrolled infection, evidence of active TB, Hepatitis B or C infection, or HIV seropositivity or infection.
Previous HCT or solid organ transplant.
CNS revascularization procedure, myocardial infarction, pulmonary embolus or deep vein thrombosis in the past 6 months.
Use of medications which significantly interfere with ruxolitinib metabolism.
Known hypersensitivity or severe reaction to ruxolitinib or any component of the conditioning regimen or its excipients.
Inability to swallow and retain oral medication (use of nasogastric or gastrostomy tube permitted).
History of malignancy except resected basal cell carcinoma or treated carcinoma in-situ.
Participation in another clinical trial involving an investigational or off-label use of a drug or device in the past 3 months.
Currently pregnant or breast feeding.
Clinically significant, uncontrolled autoimmune disease.
High-titer anti-donor specific HLA antibodies (without review and approval by Study Chair).
Participant (or guardian) inability or unwillingness to comply with the dose schedule and study evaluations, comprehend or sign informed consent and utilize a highly effective method of contraception (for participants of child-bearing potential).
Any condition that would, in the investigator's judgment, interfere with full participation in the study, pose a significant risk to the subject, or interfere with interpretation of study data.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT07252050) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sickle Cell Disease Treatment Options in Atlanta, GA

If you're searching for sickle cell disease treatment options in Atlanta, GA, this clinical trial (NCT07252050) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sickle cell disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Atlanta, GA

See all ankylosing spondylitis clinical trials recruiting in Atlanta — not just this study.

Browse Ankylosing Spondylitis Trials in Atlanta →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsSickle Cell Disease TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA